Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aβ, Aδ and C fibres) and central neurons, and affects 7–10% of the general population. Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy. Indeed, imbalances between excitatory and inhibitory somatosensory signalling, alterations in ion channels and variability in the way that pain messages are modulated in the central nervous system all have been implicated in neuropathic pain. The burden of chronic neuropathic pain seems to be related to the complexity of neuropathic symptoms, poor outcomes and difficult treatment decisions. Importantly, quality of life is impaired in patients with neuropathic pain owing to increased drug prescriptions and visits to health care providers, as well as the morbidity from the pain itself and the inciting disease. Despite challenges, progress in the understanding of the pathophysiology of neuropathic pain is spurring the development of new diagnostic procedures and personalized interventions, which emphasize the need for a multidisciplinary approach to the management of neuropathic pain.
Subscribe to Journal
Get full journal access for 1 year
only $59.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Abbott, C. A., Malik, R. A., van Ross, E. R., Kulkarni, J. & Boulton, A. J. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 34, 2220–2224 (2011).
Costigan, M., Scholz, J. & Woolf, C. J. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci. 32, 1–32 (2009). This review presents differences and commonalities among distinct chronic pain states.
Attal, N., Lanteri-Minet, M., Laurent, B., Fermanian, J. & Bouhassira, D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain 152, 2836–2843 (2011).
Torrance, N., Smith, B. H., Bennett, M. I. & Lee, A. J. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J. Pain 7, 281–289 (2006).
Finnerup, N. B. et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain 157, 1599–1606 (2016). This is an updated grading system to guide clinical diagnosis of neuropathic pain by illustrating the significance of confirmatory tests, the role of screening tools and potential uncertainties about anatomical pain distributions.
Dolgin, E. Fluctuating baseline pain implicated in failure of clinical trials. Nat. Med. 16, 1053 (2010).
Tuttle, A. H. et al. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain 156, 2616–2626 (2015). This study explores factors explaining why novel analgesics that were designed to treat neuropathic pain failed.
van Hecke, O., Austin, S. K., Khan, R. A., Smith, B. H. & Torrance, N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 155, 654–662 (2014). This is one of the first attempts to review epidemiological studies of neuropathic pain in the general population; however, the heterogeneity of the studies precluded meta-analysis, indicating a need for standardized tools and diagnostic approaches.
Bouhassira, D. et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain 153, 342–349 (2012).
Helgason, S., Petursson, G., Gudmundsson, S. & Sigurdsson, J. A. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 321, 794–796 (2000).
Daousi, C. et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet. Med. 21, 976–982 (2004).
Davies, M., Brophy, S., Williams, R. & Taylor, A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 29, 1518–1522 (2006).
Bouhassira, D., Letanoux, M. & Hartemann, A. Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study. PLoS ONE 8, e74195 (2013).
Jensen, M. P., Chodroff, M. J. & Dworkin, R. H. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 68, 1178–1182 (2007).
Solaro, C. et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 63, 919–921 (2004).
Osterberg, A., Boivie, J. & Thuomas, K. A. Central pain in multiple sclerosis — prevalence and clinical characteristics. Eur. J. Pain 9, 531–542 (2005).
Siddall, P. J., McClelland, J. M., Rutkowski, S. B. & Cousins, M. J. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 103, 249–257 (2003).
Klit, H., Finnerup, N. B., Andersen, G. & Jensen, T. S. Central poststroke pain: a population-based study. Pain 152, 818–824 (2011).
Rayment, C. et al. Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat. Med. 27, 714–721 (2013).
Bennett, M. I. et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain 153, 359–365 (2012).
Bouhassira, D. & Attal, N. Diagnosis and assessment of neuropathic pain: the saga of clinical tools. Pain 152, S74–S83 (2011). This review describes the main clinical tools that are used for the screening and measurement of neuropathic pain, focusing on the potential value and limitation of each tool.
Bouhassira, D. et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114, 29–36 (2005).
Bennett, M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 92, 147–157 (2001).
Bouhassira, D., Lanteri-Minet, M., Attal, N., Laurent, B. & Touboul, C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136, 380–387 (2008).
Freynhagen, R. et al. Screening of neuropathic pain components in patients with chronic back pain associated with nerve root compression: a prospective observational pilot study (MIPORT). Curr. Med. Res. Opin. 22, 529–537 (2006).
Borsook, D. Neurological diseases and pain. Brain 135, 320–344 (2012).
Watson, J. C. & Sandroni, P. Central neuropathic pain syndromes. Mayo Clin. Proc. 91, 372–385 (2016).
Stavros, K. & Simpson, D. M. Understanding the etiology and management of HIV-associated peripheral neuropathy. Curr. HIV/AIDS Rep. 11, 195–201 (2014).
Thakur, S., Dworkin, R. H., Haroun, O. M., Lockwood, D. N. & Rice, A. S. Acute and chronic pain associated with leprosy. Pain 156, 998–1002 (2015).
Freeman, R. Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy. Curr. Diab. Rep. 9, 423–431 (2009). This article discusses common disorders in the differential diagnosis of peripheral neuropathy.
Yang, Y. et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J. Med. Genet. 41, 171–174 (2004).
Fertleman, C. R. et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52, 767–774 (2006).
Faber, C. G. et al. Gain of function Nav1.7 mutations in idiopathic small fiber neuropathy. Ann. Neurol. 71, 26–39 (2012).
Haroutounian, S. et al. Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy. Pain 155, 1272–1279 (2014).
Vaso, A. et al. Peripheral nervous system origin of phantom limb pain. Pain 155, 1384–1391 (2014).
Serra, J. et al. Microneurographic identification of spontaneous activity in C-nociceptors in neuropathic pain states in humans and rats. Pain 153, 42–55 (2012).
Kleggetveit, I. P. et al. High spontaneous activity of C-nociceptors in painful polyneuropathy. Pain 153, 2040–2047 (2012).
Tesfaye, S., Boulton, A. J. & Dickenson, A. H. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 36, 2456–2465 (2013).
Fields, H. L., Rowbotham, M. & Baron, R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol. Dis. 5, 209–227 (1998).
Woolf, C. J. Central sensitization: implications for the diagnosis and treatment of pain. Pain 152, S2–S15 (2011).
Baron, R., Hans, G. & Dickenson, A. H. Peripheral input and its importance for central sensitization. Ann. Neurol. 74, 630–636 (2013). This article presents the main mechanisms of pain states that begin with damage to the nerves in the periphery and lead to enhanced transmitter release within the spinal cord and central sensitization — emphasizing the need for multimodal approaches that target central sensitization and/or its peripheral drivers.
Patel, R. & Dickenson, A. H. Neuronal hyperexcitability in the ventral posterior thalamus of neuropathic rats: modality selective effects of pregabalin. J. Neurophysiol. 116, 159–170 (2016).
Peyron, R. Functional brain imaging: what has it brought to our understanding of neuropathic pain? A special focus on allodynic pain mechanisms. Pain 157, S67–S71 (2016).
Gagnon, M. et al. Chloride extrusion enhancers as novel therapeutics for neurological diseases. Nat. Med. 19, 1524–1528 (2013).
Tsuda, M., Beggs, S., Salter, M. W. & Inoue, K. Microglia and intractable chronic pain. Glia 61, 55–61 (2013).
Navratilova, E., Atcherley, C. W. & Porreca, F. Brain circuits encoding reward from pain relief. Trends Neurosci. 38, 741–750 (2015).
Bannister, K. & Dickenson, A. H. What the brain tells the spinal cord. Pain 157, 2148–2151 (2016).
Yarnitsky, D. Role of endogenous pain modulation in chronic pain mechanisms and treatment. Pain 156, S24–S31 (2015).
Lewis, G. N., Rice, D. A. & McNair, P. J. Conditioned pain modulation in populations with chronic pain: a systematic review and meta-analysis. J. Pain 13, 936–944 (2012).
Yarnitsky, D., Granot, M., Nahman-Averbuch, H., Khamaisi, M. & Granovsky, Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 153, 1193–1198 (2012). This article presents a new perspective of predicting drug responses in patients with painful diabetic neuropathy based on CPM mechanisms.
Wilder-Smith, O. H., Schreyer, T., Scheffer, G. J. & Arendt-Nielsen, L. Patients with chronic pain after abdominal surgery show less preoperative endogenous pain inhibition and more postoperative hyperalgesia: a pilot study. J. Pain Palliat. Care Pharmacother. 24, 119–128 (2010).
Petersen, K. K., Graven-Nielsen, T., Simonsen, O., Laursen, M. B. & Arendt-Nielsen, L. Preoperative pain mechanisms assessed by cuff algometry are associated with chronic postoperative pain relief after total knee replacement. Pain 157, 1400–1406 (2016).
Kosek, E. & Ordeberg, G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain 88, 69–78 (2000).
Graven-Nielsen, T., Wodehouse, T., Langford, R. M., Arendt-Nielsen, L. & Kidd, B. L. Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. Arthritis Rheum. 64, 2907–2916 (2012).
Colloca, L. & Miller, F. G. Role of expectations in health. Curr. Opin. Psychiatry 24, 149–155 (2011).
Hall, K. T. et al. Conscientiousness is modified by genetic variation in catechol-O-methyltransferase to reduce symptom complaints in IBS patients. Brain Behav. 5, 39–44 (2015).
Kaptchuk, T. J. et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 336, 999–1003 (2008).
Vase, L., Robinson, M. E., Verne, G. N. & Price, D. D. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain 105, 17–25 (2003).
Vase, L., Skyt, I. & Hall, K. T. Placebo, nocebo, and neuropathic pain. Pain 157, S98–S105 (2016).
Petersen, G. L. et al. Placebo manipulations reduce hyperalgesia in neuropathic pain. Pain 153, 1292–1300 (2012).
Petersen, G. L. et al. Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions. Pain 155, 2687–2698 (2014).
Colloca, L., Lopiano, L., Lanotte, M. & Benedetti, F. Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurol. 3, 679–684 (2004).
Bennett, M. I. et al. Using screening tools to identify neuropathic pain. Pain 127, 199–203 (2007).
Freynhagen, R., Baron, R., Gockel, U. & Tolle, T. R. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr. Med. Res. Opin. 22, 1911–1920 (2006).
Bouhassira, D. et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 108, 248–257 (2004).
Baron, R., Forster, M. & Binder, A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol. 11, 999–1005 (2012).
Cruccu, G. et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur. J. Neurol. 17, 1010–1018 (2010).
Backonja, M. M. et al. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain 154, 1807–1819 (2013).
Rolke, R. et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 123, 231–243 (2006).
Baron, R. et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain 158, 261–272 (2017). This study shows how patients with neuropathic pain present with different expression patterns of sensory signs, which suggests various mechanisms of neuropathic pain generation.
Magerl, W. et al. Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. Pain 151, 598–605 (2010).
Haanpaa, M. et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 152, 14–27 (2011).
Garcia-Larrea, L. Objective pain diagnostics: clinical neurophysiology. Neurophysiol. Clin. 42, 187–197 (2012).
Truini, A. et al. Pathophysiology of pain in postherpetic neuralgia: a clinical and neurophysiological study. Pain 140, 405–410 (2008).
Truini, A. et al. Differential involvement of A-delta and A-beta fibres in neuropathic pain related to carpal tunnel syndrome. Pain 145, 105–109 (2009).
Truini, A. et al. Mechanisms of pain in distal symmetric polyneuropathy: a combined clinical and neurophysiological study. Pain 150, 516–521 (2010).
Truini, A., Garcia-Larrea, L. & Cruccu, G. Reappraising neuropathic pain in humans — how symptoms help disclose mechanisms. Nat. Rev. Neurol. 9, 572–582 (2013).
Truini, A. et al. Trigeminal small-fibre function assessed with contact heat evoked potentials in humans. Pain 132, 102–107 (2007).
Hansen, N. et al. Amplitudes of pain-related evoked potentials are useful to detect small fiber involvement in painful mixed fiber neuropathies in addition to quantitative sensory testing — an electrophysiological study. Front. Neurol. 6, 244 (2015).
Tesfaye, S. et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33, 2285–2293 (2010).
Lauria, G. et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur. J. Neurol. 17, 903–912 (2010).
Nolano, M. et al. Cutaneous innervation of the human face as assessed by skin biopsy. J. Anat. 222, 161–169 (2013).
Truini, A. et al. Does the epidermal nerve fibre density measured by skin biopsy in patients with peripheral neuropathies correlate with neuropathic pain? Pain 155, 828–832 (2014). This study presents the advantages and limitations of using skin biopsy and epidermal nerve fibre density measurement for the diagnosis of neuropathic pain.
Papanas, N. & Ziegler, D. Corneal confocal microscopy: recent progress in the evaluation of diabetic neuropathy. J. Diabetes Investig. 6, 381–389 (2015).
Ziegler, D. et al. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes 63, 2454–2463 (2014).
Tavakoli, M. et al. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Exp. Neurol. 223, 245–250 (2010).
Smith, B. H. & Torrance, N. Epidemiology of neuropathic pain and its impact on quality of life. Curr. Pain Headache Rep. 16, 191–198 (2012).
Oxman, M. N. et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352, 2271–2284 (2005).
Schmader, K. E. et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin. Infect. Dis. 54, 922–928 (2012).
Lal, H. et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N. Engl. J. Med. 372, 2087–2096 (2015). This randomized, placebo-controlled, phase III study evaluates the efficacy and safety of a herpes zoster virus subunit vaccine; the vaccine reduced the risk of herpes zoster infection similarly in adults across several age brackets.
Cunningham, A. L. et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N. Engl. J. Med. 375, 1019–1032 (2016).
Gewandter, J. S. et al. Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain 156, 1184–1197 (2015).
Dworkin, R. H. et al. Recommendations for the management of herpes zoster. Clin. Infect. Dis. 44, S1–S26 (2007).
Smith, A. G. et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 29, 1294–1299 (2006).
Attal, N. et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol. 13, 1153–1169 (2006).
Dworkin, R. H. et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132, 237–251 (2007).
Moulin, D. et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res. Manag. 19, 328–335 (2014).
Tan, T., Barry, P., Reken, S., Baker, M. & Guideline Development Group. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ 340, c1079 (2010).
Attal, N. et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol. 17, 1113–e88 (2010).
Finnerup, N. B. & Attal, N. Pharmacotherapy of neuropathic pain: time to rewrite the rulebook? Pain Manag. 6, 1–3 (2016).
Finnerup, N. B. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 14, 162–173 (2015). This systematic review updates the recommendations for the pharmacological management of neuropathic pain, emphasizing that modest efficacy, considerable placebo responses, heterogeneous diagnostic criteria and poor phenotypic profiling account for moderate trial outcomes and unmet needs of the patients.
Yalcin, I. et al. β2-Adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann. Neurol. 65, 218–225 (2009).
Luo, Z. D. et al. Upregulation of dorsal root ganglion α2δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J. Neurosci. 21, 1868–1875 (2001).
Vinik, A. I. et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 16, 251 (2016).
Tesfaye, S. et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study” — a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 154, 2616–2625 (2013).
Binder, A. et al. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin. Drug Investig. 29, 393–408 (2009).
Demant, D. T. et al. Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study. Pain 156, 2234–2244 (2015).
Backonja, M. et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 7, 1106–1112 (2008).
Burness, C. B. & McCormack, P. L. Capsaicin 8% patch: a review in peripheral neuropathic pain. Drugs 76, 123–134 (2016).
Attal, N. et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 15, 555–565 (2016). This randomized, double-blind, placebo-controlled trial in peripheral neuropathic pain indicates that botulinum toxin A reduces pain intensity over 24 weeks compared with a placebo treatment.
Shackleton, T. et al. The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 122, 61–71 (2016).
Lakhan, S. E., Velasco, D. N. & Tepper, D. Botulinum toxin-A for painful diabetic neuropathy: a meta-analysis. Pain Med. 16, 1773–1780 (2015).
Ray W. A., Chung, C. P., Murray, K. T., Hall, K. & Stein, C. M. Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. JAMA 315, 2415–2423 (2016).
Emery, E. C., Luiz, A. P. & Wood, J. N. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief. Expert Opin. Ther. Targets 20, 975–983 (2016).
Rice, A. S. et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 383, 1637–1647 (2014).
Chen, G., Park, C. K., Xie, R. G. & Ji, R. R. Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-beta secretion. J. Clin. Invest. 125, 3226–3240 (2015).
Braz, J. M. et al. Forebrain GABAergic neuron precursors integrate into adult spinal cord and reduce injury-induced neuropathic pain. Neuron 74, 663–675 (2012).
Cruccu, G. et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur. J. Neurol. 14, 952–970 (2007).
Dworkin, R. H. et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain 154, 2249–2261 (2013).
Mekhail, N. A. et al. Retrospective review of 707 cases of spinal cord stimulation: indications and complications. Pain Pract. 11, 148–153 (2011).
Eldabe, S., Buchser, E. & Duarte, R. V. Complications of spinal cord stimulation and peripheral nerve stimulation techniques: a review of the literature. Pain Med. 17, 325–336 (2016).
Bhatia, A., Flamer, D. & Shah, P. S. Perineural steroids for trauma and compression-related peripheral neuropathic pain: a systematic review and meta-analysis. Can. J. Anaesth. 62, 650–662 (2015).
Cohen, S. P., Bicket, M. C., Jamison, D., Wilkinson, I. & Rathmell, J. P. Epidural steroids: a comprehensive, evidence-based review. Reg. Anesth. Pain Med. 38, 175–200 (2013).
Chou, R. et al. Epidural corticosteroid injections for radiculopathy and spinal stenosis: a systematic review and meta-analysis. Ann. Intern. Med. 163, 373–381 (2015).
Melzack, R. & Wall, P. D. Pain mechanisms: a new theory. Science 150, 971–979 (1965).
Yearwood, T. L., Hershey, B., Bradley, K. & Lee, D. Pulse width programming in spinal cord stimulation: a clinical study. Pain Physician 13, 321–335 (2010).
De Ridder, D., Plazier, M., Kamerling, N., Menovsky, T. & Vanneste, S. Burst spinal cord stimulation for limb and back pain. World Neurosurg. 80, 642–649.e1 (2013).
Russo, M. & Van Buyten, J. P. 10-kHz high-frequency SCS therapy: a clinical summary. Pain Med. 16, 934–942 (2015).
Manca, A. et al. Quality of life, resource consumption and costs of spinal cord stimulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial). Eur. J. Pain 12, 1047–1058 (2008).
Kumar, K. & Rizvi, S. Cost-effectiveness of spinal cord stimulation therapy in management of chronic pain. Pain Med. 14, 1631–1649 (2013).
Deer, T. R. et al. The appropriate use of neurostimulation: new and evolving neurostimulation therapies and applicable treatment for chronic pain and selected disease states. Neuromodulation Appropriateness Consensus Committee. Neuromodulation 17, 599–615 (2014).
North, R. B. et al. Spinal cord stimulation versus re-operation in patients with failed back surgery syndrome: an international multicenter randomized controlled trial (EVIDENCE study). Neuromodulation 14, 330–335 (2011).
Kumar, K. et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome. Pain 132, 179–188 (2007).
Simpson, E. L., Duenas, A., Holmes, M. W., Papaioannou, D. & Chilcott, J. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation. Health Technol. Assess. 13, 1–154 (2009).
Kumar, K. et al. The effects of spinal cord stimulation in neuropathic pain are sustained: a 24-month follow-up of the prospective randomized controlled multicenter trial of the effectiveness of spinal cord stimulation. Neurosurgery 63, 762–770 (2008).
Kemler, M. A., De Vet, H. C., Barendse, G. A., Van Den Wildenberg, F. A. & Van Kleef, M. The effect of spinal cord stimulation in patients with chronic reflex sympathetic dystrophy: two years’ follow-up of the randomized controlled trial. Ann. Neurol. 55, 13–18 (2004).
de Vos, C. C. et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain 155, 2426–2431 (2014).
Slangen, R. et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. Diabetes Care 37, 3016–3024 (2014).
Cruccu, G. et al. EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur. J. Neurol. 23, 1489–1499 (2016). These up-to-date guidelines on neurostimulation for neuropathic pain by the European Academy of Neurology indicate poor-to-moderate quality of evidence for non-invasive and invasive neurostimulation.
Campbell, C. M., Jamison, R. N. & Edwards, R. R. Psychological screening/phenotyping as predictors for spinal cord stimulation. Curr. Pain Headache Rep. 17, 307 (2013).
Campbell, C. M. et al. Dynamic pain phenotypes are associated with spinal cord stimulation-induced reduction in pain: a repeated measures observational pilot study. Pain Med. 16, 1349–1360 (2015).
Krames, E. S. The role of the dorsal root ganglion in the development of neuropathic pain. Pain Med. 15, 1669–1685 (2014).
Petersen, E. A. & Slavin, K. V. Peripheral nerve/field stimulation for chronic pain. Neurosurg. Clin. N. Am. 25, 789–797 (2014).
Liem, L. et al. One-year outcomes of spinal cord stimulation of the dorsal root ganglion in the treatment of chronic neuropathic pain. Neuromodulation 18, 41–48 (2015).
Sukul, V. V. & Slavin, K. V. Deep brain and motor cortex stimulation. Curr. Pain Headache Rep. 18, 427 (2014).
Moore, N. Z., Lempka, S. F. & Machado, A. Central neuromodulation for refractory pain. Neurosurg. Clin. N. Am. 25, 77–83 (2014).
Lefaucheur, J. P. Cortical neurostimulation for neuropathic pain: state of the art and perspectives. Pain 157, S81–S89 (2016). In this paper, various types of stimulation, including EMCS, rTMS and anodal tDCS, are discussed as therapeutic strategies when neuropathic pain is lateralized and stimulation is applied to the motor cortex contralateral to the pain side.
Lefaucheur, J. P. et al. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin. Neurophysiol. 128, 56–92 (2016).
Keifer, O. P. Jr, Riley, J. P. & Boulis, N. M. Deep brain stimulation for chronic pain: intracranial targets, clinical outcomes, and trial design considerations. Neurosurg. Clin. N. Am. 25, 671–692 (2014).
Prager, J. et al. Best practices for intrathecal drug delivery for pain. Neuromodulation 17, 354–372 (2014).
Bolash, R. & Mekhail, N. Intrathecal pain pumps: indications, patient selection, techniques, and outcomes. Neurosurg. Clin. N. Am. 25, 735–742 (2014).
Deer, T. R. et al. Polyanalgesic Consensus Conference — 2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation 15, 467–482 (2012).
Pope, J. E., Deer, T. R., Bruel, B. M. & Falowski, S. Clinical uses of intrathecal therapy and its placement in the pain care algorithm. Pain Pract. 16, 1092–1106 (2016).
Dobson, J. L., McMillan, J. & Li, L. Benefits of exercise intervention in reducing neuropathic pain. Front. Cell Neurosci. 8, 102 (2014).
Kluding, P. M. et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J. Diabetes Compl. 26, 424–429 (2012).
Smart, K. M., Wand, B. M. & O'Connell, N. E. Physiotherapy for pain and disability in adults with complex regional pain syndrome (CRPS) types I and II. Cochrane Database Syst. Rev. 2, CD010853 (2016).
Thieme, H., Morkisch, N., Rietz, C., Dohle, C. & Borgetto, B. The efficacy of movement representation techniques for treatment of limb pain — a systematic review and meta-analysis. J. Pain 17, 167–180 (2016).
Eccleston, C. & Crombez, G. Worry and chronic pain: a misdirected problem solving model. Pain 132, 233–236 (2007).
DOLORisk. Objectives. DOLORiskhttp://dolorisk.eu/project/objectives (2015).
Williams, A. C., Eccleston, C. & Morley, S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst. Rev. 11, CD007407 (2012).
Eccleston, C. et al. Psychological therapies (internet-delivered) for the management of chronic pain in adults. Cochrane Database Syst. Rev. 2, CD010152 (2014).
Eccleston, C., Hearn, L. & Williams, A. C. Psychological therapies for the management of chronic neuropathic pain in adults. Cochrane Database Syst. Rev. 10, CD011259 (2015). This systematic review indicates a lack of evidence on the efficacy and safety of psychological interventions for chronic neuropathic pain.
Moore, A., Derry, S., Eccleston, C. & Kalso, E. Expect analgesic failure; pursue analgesic success. BMJ 346, f2690 (2013).
Otis, J. D. et al. A randomized controlled pilot study of a cognitive-behavioral therapy approach for painful diabetic peripheral neuropathy. J. Pain 14, 475–482 (2013).
Eccleston, C. Embodied: The Psychology of Physical Sensation (Oxford Univ. Press, 2016).
Eccleston, C., Tabor, A., Edwards, R. T. & Keogh, E. Psychological approaches to coping with pain in later life. Clin. Geriatr. Med. 32, 763–771 (2016).
Morley, S., Williams, A. & Eccleston, C. Examining the evidence about psychological treatments for chronic pain: time for a paradigm shift? Pain 154, 1929–1931 (2013).
Duggan, G. B. et al. Qualitative evaluation of the SMART2 self-management system for people in chronic pain. Disabil. Rehabil. Assist. Technol. 10, 53–60 (2015).
Meyer-Rosberg, K. et al. Peripheral neuropathic pain — a multidimensional burden for patients. Eur. J. Pain 5, 379–389 (2001).
Gordh, T. E. et al. Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain 138, 255–266 (2008).
Ahroni, J. H. & Boyko, E. J. Responsiveness of the SF-36 among veterans with diabetes mellitus. J. Diabetes Compl. 14, 31–39 (2000).
Van Acker, K. et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 35, 206–213 (2009).
Torrance, N. et al. Estimating the burden of disease in chronic pain with and without neuropathic characteristics: does the choice between the EQ-5D and SF-6D matter? Pain 155, 1996–2004 (2014). This study presents the advantage of using EQ-5D over SF-6D for estimating the burden of chronic pain in those with or without neuropathic clinical characteristics.
Geelen, C. C., Kindermans, H. P., van den Bergh, J. P. & Verbunt, J. A. Perceived physical activity decline as a mediator in the relationship between pain catastrophizing, disability, and quality of life in patients with painful diabetic neuropathy. Pain Pract.http://dx.doi.org/10.1111/papr.12449 (2016).
Backonja, M. et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280, 1831–1836 (1998).
Rowbotham, M., Harden, N., Stacey, B., Bernstein, P. & Magnus-Miller, L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280, 1837–1842 (1998).
Ogawa, K., Fujikoshi, S., Montgomery, W. & Alev, L. Correlation between pain response and improvements in patient-reported outcomes and health-related quality of life in duloxetine-treated patients with diabetic peripheral neuropathic pain. Neuropsychiatr. Dis. Treat. 11, 2101–2107 (2015).
Duarte, R. V., Andronis, L., Lenders, M. W. & de Vos, C. C. Quality of life increases in patients with painful diabetic neuropathy following treatment with spinal cord stimulation. Qual. Life Res. 25, 1771–1777 (2016).
Dworkin, R. H. et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 153, 1148–1158 (2012).
Gewandter, J. S. et al. Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain 155, 1683–1695 (2014).
Dworkin, R. H. et al. Assay sensitivity and study features in neuropathic pain trials: an ACTTION meta-analysis. Neurology 81, 67–75 (2013).
Farrar, J. T. et al. Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study. Pain 155, 1622–1631 (2014).
Attal, N. et al. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur. J. Pain 15, 441–443 (2011).
Finnerup, N. B. & Jensen, T. S. Mechanisms of disease: mechanism-based classification of neuropathic pain — a critical analysis. Nat. Clin. Pract. Neurol. 2, 107–115 (2006).
Campbell, C. M. et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain 153, 1815–1823 (2012).
Demant, D. T. et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 155, 2263–2273 (2014).
Dworkin, R. H., McDermott, M. P., Farrar, J. T., O'Connor, A. B. & Senn, S. Interpreting patient treatment response in analgesic clinical trials: implications for genotyping, phenotyping, and personalized pain treatment. Pain 155, 457–460 (2014). This article indicates within-patient variation and treatment-by-patient interaction as two sources of variance that contribute to differences between patients in responding to efficacious analgesic treatments.
Edwards, R. R. et al. Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain 157, 1851–1871 (2016). This article proposes core phenotyping domains to estimate the likelihood to experience pain relief. Recommended measures for each domain include psychosocial factors, symptom characteristics, sleep patterns, responses to noxious stimulation, endogenous pain-modulatory processes and response to pharmacological challenge.
Bennett, D. L. & Woods, C. G. Painful and painless channelopathies. Lancet Neurol. 13, 587–599 (2014). This paper provides an introduction to the discovery of genetic variants that can alter the individual perception of pain, including the inactivating mutations in SCN9A, resulting in congenital insensitivity to pain. Furthermore, other genetic variations that contribute to risk or severity of more complex pain phenotypes are presented.
Waxman, S. G. et al. Sodium channel genes in pain-related disorders: phenotype–genotype associations and recommendations for clinical use. Lancet Neurol. 13, 1152–1160 (2014).
Cregg, R., Cox, J. J., Bennett, D. L., Wood, J. N. & Werdehausen, R. Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV1.7 sodium channels. Br. J. Pharmacol. 171, 4455–4463 (2014).
Yang, Y. et al. Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a NaV1.7 mutant channel. Nat. Commun. 3, 1186 (2012).
Geha, P. et al. Pharmacotherapy for pain in a family with inherited erythromelalgia guided by genomic analysis and functional profiling. JAMA Neurol. 73, 659–667 (2016).
Cao, L. et al. Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia. Sci Transl Med. 8, 335ra56 (2016).
Krause, S. J. & Backonja, M. M. Development of a neuropathic pain questionnaire. Clin. J. Pain 19, 306–314 (2003).
Portenoy, R. Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr. Med. Res. Opin. 22, 1555–1565 (2006).
Bierhaus, A. et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat. Med. 18, 926–933 (2012).
Burma, N. E., Leduc-Pessah, H., Fan, C. Y. & Trang, T. Animal models of chronic pain: advances and challenges for clinical translation. J. Neurosci. Res.http://dx.doi.org/10.1002/jnr.23768 (2016).
Okun, A. et al. Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain. Pain 157, 2731–2738 (2016).
Patel, R. & Dickenson, A. H. Mechanisms of the gabapentinoids and alpha 2 delta-1 calcium channel subunit in neuropathic pain. Pharmacol. Res. Perspect. 4, e00205 (2016).
Dias, Q. M. et al. The effect of intrathecal gabapentin on neuropathic pain is independent of the integrity of the dorsolateral funiculus in rats. Life Sci. 91, 837–842 (2012).
Rauck, R. et al. Intrathecal gabapentin to treat chronic intractable noncancer pain. Anesthesiology 119, 675–686 (2013).
Nir, R. R. & Yarnitsky, D. Conditioned pain modulation. Curr. Opin. Support. Palliat. Care 9, 131–137 (2015).
Valeriani, M., Pazzaglia, C., Cruccu, G. & Truini, A. Clinical usefulness of laser evoked potentials. Neurophysiol. Clin. 42, 345–353 (2012).
L.C. acknowledges support from the UMB and the National Institute of Dental and Craniofacial Research (NIDCR) at the US NIH (R01DE025946). A.H.D. and D.L.B. acknowledge support from the Wellcome Trust Pain Consortium. R.B. acknowledges support from the European Union Project No. 633491: DOLORisk, IMI Europain, the German Federal Ministry of Education and Research (ERA_NET NEU-RON/IM-PAIN Project) and the German Research Network on Neuropathic Pain, NoPain system biology and the German Research Foundation. R.B. also acknowledges support from the German Federal Ministry of Education and Research (BMBF), the ERA_NET NEURON/IM-PAIN Project (01EW1503), the German Research Network on Neuropathic Pain (01EM0903), NoPain system biology (0316177C) and the German Research Foundation (DFG). D.Y. acknowledges support from the Israel Science Foundation, European Horizons 2020 and the US Department of Defense. S.N.R. acknowledges support from the NIH (NS26363).
L.C. has received lecture honoraria (Georgetown University and Stanford University) and has acted as speaker or consultant for Grünenthal and Emmi Solution. R.B. is an industry member of AstraZeneca, Pfizer, Esteve, UCB Pharma, Sanofi Aventis, Grünenthal, Eli Lilly and Boehringer Ingelheim; has received lecture honoraria from Pfizer, Genzyme, Grünenthal, Mundipharma, Sanofi Pasteur, Medtronic Inc. Neuromodulation, Eisai, Lilly, Boehringer Ingelheim, Astellas, Desitin, Teva Pharma, Bayer-Schering, MSD and Seqirus; and has served as a consultant for Pfizer, Genzyme, Grünenthal, Mundipharma, Sanofi Pasteur, Medtronic Inc. Neuromodulation, Eisai, Lilly, Boehringer Ingelheim Pharma, Astellas, Desitin, Teva Pharma, Bayer-Schering, MSD, Novartis, Bristol-Myers Squibb, Biogen idec, AstraZeneca, Merck, AbbVie, Daiichi Sankyo, Glenmark Pharmaceuticals, Seqirus, Genentech, Galapagos NV and Kyowa Hakko Kirin. A.H.D. has acted as speaker or consultant forSeqirus, Grünenthal, Allergan and Mundipharma. D.B. has acted as a consultant for Grünenthal, Pfizer and Indivior. D.L.B. has acted as a consultant for Abide, Eli Lilly, Mundipharma, Pfizer and Teva. D.Y. received a lecture honorarium from Pfizer and holds equity in BrainsGate and Theranica. R.F. has acted as an advisory board member for Abide, Astellas, Biogen, Glenmark, Hydra, Novartis and Pfizer. A.T. has received research funding, lecture honoraria and acted as speaker or consultant for Mundipharma, Pfizer, Grünenthal and Angelini Pharma. N.A. has received honoraria for participation in advisory boards or speaker bureau by Astellas, Teva, Mundipharma, Johnson and Johnson, Novartis and Sanofi Pasteur MSD. N.B.F. has received honoraria for participation in advisory boards from Teva Pharmaceuticals, Novartis and Grünenthal, and research support from EUROPAIN Investigational Medicines Initiative (IMI). E.K. has served on the advisory boards of Orion Pharma and Grünenthal, and received lecture honoraria from Orion Pharma and AstraZeneca. R.H.D. has received research grants and contracts from the US FDA and the US NIH, and compensation for activities involving clinical trial research methods from Abide, Aptinyx, Astellas, Boston Scientific, Centrexion, Dong-A, Eli Lilly, Glenmark, Hope, Hydra, Immune, Novartis, NsGene, Olatec, Phosphagenics, Quark, Reckitt Benckiser, Relmada, Semnur, Syntrix, Teva, Trevena and Vertex. S.N.R. has received a research grant from Medtronic Inc. and honoraria for participation in advisory boards of Allergan, Daiichi Sankyo, Grünenthal USA Inc. and Lexicon Pharmaceuticals. C.E. and T.L. declare no competing interests.
About this article
Cite this article
Colloca, L., Ludman, T., Bouhassira, D. et al. Neuropathic pain. Nat Rev Dis Primers 3, 17002 (2017). https://doi.org/10.1038/nrdp.2017.2
Internal Medicine (2021)
MiR-15a attenuates peripheral nerve injury-induced neuropathic pain by targeting AKT3 to regulate autophagy
Genes & Genomics (2020)
Botulinum Toxin and Neuronal Regeneration after Traumatic Injury of Central and Peripheral Nervous System
Epigenetic restoration of voltage‐gated potassium channel Kv1.2 alleviates nerve injury‐induced neuropathic pain
Journal of Neurochemistry (2020)
Reliability and Validity of the Boston Bedside Quantitative Sensory Testing Battery for Neuropathic Pain
Pain Medicine (2020)